Matthias Eder

19.1k total citations · 10 hit papers
199 papers, 13.2k citations indexed

About

Matthias Eder is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matthias Eder has authored 199 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 61 papers in Radiology, Nuclear Medicine and Imaging and 55 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matthias Eder's work include Radiopharmaceutical Chemistry and Applications (52 papers), Prostate Cancer Treatment and Research (47 papers) and Acute Myeloid Leukemia Research (41 papers). Matthias Eder is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (52 papers), Prostate Cancer Treatment and Research (47 papers) and Acute Myeloid Leukemia Research (41 papers). Matthias Eder collaborates with scholars based in Germany, United States and France. Matthias Eder's co-authors include Uwe Haberkorn, Michaela Scherr, Klaus Kopka, Ali Afshar‐Oromieh, Walter Mier, Martin Schäfer, Frederik L. Giesel, Arnold Ganser, Ulrike Bauder‐Wüst and Michael Eisenhut and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Matthias Eder

188 papers receiving 13.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia

2006 964 citations Axel Schambach, Karin Battmer et al. profile →
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

2014 785 citations Frederik L. Giesel, Matthias Eder et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

2013 712 citations Matthias Eder, Frederik L. Giesel et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
⁶⁸Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging

2012 688 citations Matthias Eder, Martin Schäfer et al. profile →
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

2015 464 citations Martin Schäfer, Ulrike Bauder‐Wüst et al. Journal of Nuclear Medicine profile →
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617

2016 463 citations Frederik L. Giesel, Matthias Eder et al. Journal of Nuclear Medicine profile →
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

2017 400 citations Frederik L. Giesel, Matthias Eder et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions

2015 332 citations Matthias Eder, Frederik L. Giesel et al. Journal of Nuclear Medicine profile →
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

2014 317 citations Matthias Eder, Ulrike Bauder‐Wüst et al. Pharmaceuticals profile →
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

2022 171 citations Matthias Eder et al. Pharmaceuticals profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthias Eder Germany	57	6.1k	5.9k	3.3k	3.0k	1.6k	199	13.2k
Joel S. Greenberger United States	68	3.2k 0.5×	3.6k 0.6×	3.1k 0.9×	7.7k 2.6×	2.4k 1.5×	447	18.6k
Christopher J. Logothetis United States	75	9.6k 1.6×	2.9k 0.5×	7.9k 2.4×	6.9k 2.3×	1.1k 0.7×	458	20.8k
Christian Peschel Germany	69	3.1k 0.5×	1.7k 0.3×	5.2k 1.6×	5.8k 1.9×	3.1k 1.9×	345	16.8k
Anders Bjartell Sweden	61	7.3k 1.2×	1.7k 0.3×	2.5k 0.8×	4.3k 1.4×	366 0.2×	345	13.5k
David G. Kirsch United States	53	3.8k 0.6×	1.7k 0.3×	4.1k 1.2×	6.1k 2.0×	302 0.2×	263	13.3k
David F. Jarrard United States	49	5.0k 0.8×	1.3k 0.2×	2.1k 0.6×	4.0k 1.3×	406 0.3×	207	10.0k
Silke Gillessen Switzerland	46	4.5k 0.7×	1.4k 0.2×	3.3k 1.0×	2.7k 0.9×	356 0.2×	250	9.9k
Anas Younes United States	77	2.7k 0.5×	2.0k 0.3×	10.9k 3.3×	6.5k 2.2×	1.8k 1.1×	529	22.1k
William Kevin Kelly United States	46	6.3k 1.0×	1.9k 0.3×	3.9k 1.2×	5.0k 1.7×	831 0.5×	244	11.9k
Nai‐Kong V. Cheung United States	69	1.7k 0.3×	2.3k 0.4×	5.5k 1.7×	6.8k 2.2×	661 0.4×	392	16.7k

Countries citing papers authored by Matthias Eder

Since Specialization

Citations

This map shows the geographic impact of Matthias Eder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Eder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Eder more than expected).

Fields of papers citing papers by Matthias Eder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Eder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Eder. The network helps show where Matthias Eder may publish in the future.

Co-authorship network of co-authors of Matthias Eder

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Eder. A scholar is included among the top collaborators of Matthias Eder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Eder. Matthias Eder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Penack, Olaf, Christophe Peczynski, Nicolaus Kröger, et al.. (2025). GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party. Leukemia. 39(6). 1503–1511.

Bazarbachi, Ali, Jacques‐Emmanuel Galimard, Gérard Socié, et al.. (2025). Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. American Journal of Hematology. 100(8). 1374–1386.

Fleischer, Lisa, Ruth Esser, Steven R. Talbot, et al.. (2025). Combination of targeted pharmacotherapy and immunotherapy with anti‐CD19 CAR NK cells in acute lymphoblastic leukemia. HemaSphere. 9(10). e70238–e70238.

Lahdenranta, Johanna, et al.. (2024). Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide. Theranostics. 14(12). 4701–4712. 9 indexed citations

Gabdoulline, Razif, Rabia Shahswar, Arnold Kloos, et al.. (2024). Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 847–847. 1 indexed citations

Mix, Michael, Gabriele Niedermann, Simon K. B. Spohn, et al.. (2024). Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. 14(6). 2560–2572. 6 indexed citations

Odak, Ivan, Lennart Riemann, J. Schneider, et al.. (2024). Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time. Frontiers in Immunology. 15. 1298598–1298598. 2 indexed citations

Müller, Marius, Sture Lindegren, Emma Aneheim, et al.. (2024). Development and Preclinical Evaluation of [²¹¹At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer. Journal of Nuclear Medicine. 65(4). 593–599. 12 indexed citations

Ruutu, Tapani, Christophe Peczynski, Nicolaus Kröger, et al.. (2023). The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. Bone Marrow Transplantation. 59(2). 255–263. 3 indexed citations

10.

Nagler, Arnon, Myriam Labopin, Nicolaus Kröger, et al.. (2023). The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplantation. 58(12). 1339–1347.

11.

Matthias, Jessica, Martin Schäfer, Jana Schmidt, et al.. (2022). A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. Pharmaceuticals. 15(3). 267–267. 6 indexed citations

12.

Möhn, Nora, Lea Grote‐Levi, Victoria Panagiota, et al.. (2022). Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. SHILAP Revista de lepidopterología. 4(1). 1–1. 18 indexed citations

13.

Matthias, Jessica, Johann Engelhardt, Martin Schäfer, et al.. (2021). Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Research. 81(8). 2234–2245. 21 indexed citations

14.

Stadlbauer, Sven, Mareike Roscher, Wael Khoder, et al.. (2021). The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. European Journal of Nuclear Medicine and Molecular Imaging. 48(6). 2057–2058. 27 indexed citations

15.

Cardinale, Jens, Mareike Roscher, Martin Schäfer, et al.. (2020). Development of PSMA-1007-Related Series of ¹⁸F-Labeled Glu-Ureido-Type PSMA Inhibitors. Journal of Medicinal Chemistry. 63(19). 10897–10907. 24 indexed citations

16.

Eder, Matthias, Silvia Pavan, Ulrike Bauder‐Wüst, et al.. (2019). Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Research. 79(4). 841–852. 49 indexed citations

17.

Dallmann, Iris, Andreas Pich, Jan Hegermann, et al.. (2019). Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. PLoS ONE. 14(12). e0225977–e0225977. 3 indexed citations

18.

Zamboglou, Constantinos, Matthias Eiber, Matthias Eder, et al.. (2018). Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology. 8. 8–16. 6 indexed citations

19.

Battmer, Karin, Arnold Ganser, Denise Hilfiker‐Kleiner, et al.. (2018). miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. PLoS ONE. 13(10). e0204942–e0204942. 3 indexed citations

20.

Quelle, Frederick W., Noriko Sato, Bruce A. Witthuhn, et al.. (1994). JAK2 Associates with the β _c Chain of the Receptor for Granulocyte-Macrophage Colony-Stimulating Factor, and Its Activation Requires the Membrane-Proximal Region. Molecular and Cellular Biology. 14(7). 4335–4341. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact